Altruist Biologics secures NMPA priority review for localised production of multinational client’s biologic
Altruist Biologics has supported the acceptance and priority review of a multinational client's application to manufacture an existing overseas-developed biologic in China. The milestone demonstrates the relevance of China's 2024 localisation framework, but the client's identity, the medicine and the financial terms remain undisclosed.